Ceragenix Announces Results of a Comparison Study of the Safety and Efficacy of EpiCeram® Cream for the Treatment of Mild to Moderate Pediatric Atopic Dermatitis

GraphicGraphic

Back to: News Release
Daily (twice) applications of Elidel(R) Cream produced significant reductions in EASI scores at Day 28 compared to baseline. While twice daily applications of EpiCeram(R) did not produce statistically significant improvement in EASI scores at Week 4, the overall improvement produced by EpiCeram(R) was not statistically significantly different from that produced by Elidel(R) (no significant difference between treatment effects after 28 days as measured by EASI). (Graphic: Business Wire)
Daily (twice) applications of Elidel(R) Cream produced significant reductions in EASI scores at Day 28 compared to baseline. While twice daily applications of EpiCeram(R) did not produce statistically significant improvement in EASI scores at Week 4, the overall improvement produced by EpiCeram(R) was not statistically significantly different from that produced by Elidel(R) (no significant difference between treatment effects after 28 days as measured by EASI). (Graphic: Business Wire)

Download Formats

Share This Graphic

URL:

Smart Multimedia Gallery

Daily (twice) applications of Elidel(R) Cream produced significant reductions in EASI scores at Day 28 compared to baseline. While twice daily applications of EpiCeram(R) did not produce statistically significant improvement in EASI scores at Week 4, the overall improvement produced by EpiCeram(R) was not statistically significantly different from that produced by Elidel(R) (no significant difference between treatment effects after 28 days as measured by EASI). (Graphic: Business Wire)
Daily (twice) applications of Elidel(R) Cream produced significant reductions in EASI scores at Day 28 compared to baseline. While twice daily applications of EpiCeram(R) did not produce statistically significant improvement in EASI scores at Week 4, the overall improvement produced by EpiCeram(R) was not statistically significantly different from that produced by Elidel(R) (no significant difference between treatment effects after 28 days as measured by EASI). (Graphic: Business Wire)Graphic

Daily (twice) applications of Elidel(R) Cream produced significant reductions in EASI scores at Day 28 compared to baseline. While twice daily applications of EpiCeram(R) did not produce statistically significant improvement in EASI scores at Week 4, the overall improvement produced by EpiCeram(R) was not statistically significantly different from that produced by Elidel(R) (no significant difference between treatment effects after 28 days as measured by EASI). (Graphic: Business Wire)

Better Be Business Wired.

Business Wire is the leading source for press releases, photos, multimedia and regulatory filings from companies and groups throughout the world.